Company: DNLI
Filing Date: 2025-04-17
Form Type: DEF 14A
Source: 0001714899-25-000087
Chunk: 13

Company: Denali Therapeutics Inc.
Filing Date: 2025-04-17
Form: DEF 14A
Chunk 13
---
 Director |     |     2015 |     |    2026 |     |                      — |
| Jay Flatley(1)(2)              |     | I     |     |  72 |     | Director                                        |     |     2015 |     |    2027 |     |                      — |
| Marc Tessier-Lavigne, Ph.D.(3) |     | I     |     |  65 |     | Director                                        |     |     2015 |     |    2027 |     |                      — |
| Nancy A. Thornberry(2)         |     | I     |     |  68 |     | Director                                        |     |     2021 |     |    2027 |     |                      — |
| 3.  Departing Directors        |     |       |     |     |     |                                                 |     |          |     |         |     |                        |
| Vicki Sato, Ph.D.(3)           |     | II    |     |  76 |     | Chairperson of the Board                        |     |     2015 |     |    2025 |     |                      — |
| Erik Harris(1)                 |     | II    |     |  55 |     | Director                                        |     |     2022 |     |    2025 |     |                      — |

(1) Member of our audit committee.

(2) Member of our compensation committee.

(3) Member of our corporate governance and nominating committee.

<div align='center'>-9-</div>

#### Nominees for Director
Julian C. Baker is a Managing Member of Baker Bros. Advisors LP (“BBA”), a biotechnology-focused investment adviser to fund partnerships whose investors are primarily endowments and foundations. Mr. Baker founded BBA, together with his brother Felix Baker, in 2000. Prior to BBA, Mr. Baker was a portfolio manager at Tisch Financial Management from 1994 to 1999. Previously, Mr. Baker was employed from 1988 to 1993 by the private equity investment arm of Credit Suisse First Boston Corporation. Mr. Baker currently serves on the boards of directors of public companies Acadia Pharmaceuticals, Inc., Incyte Corporation, Madrigal Pharmaceuticals, Inc., and Prelude Therapeutics, Inc. Mr. Baker holds an A.B. from Harvard University.

We believe Mr. Baker’s extensive experience investing in life sciences